United States of America based
Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Convergent DesignTM combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and plans on using its platform to both develop an internal pipeline of therapeutics as well as enable partners.
TechnologiesAI Companies (Drug Discovery)
Our Convergent Design™ platform combines experimental and computational advances into a systematic and repeatable process for cell optimization.
No pipelines published yet
No services posted yet